The science can be right and the transfer still go wrong.
The path from promising data to a dependable, scalable manufacturing process has never been more challenging. With development budgets under pressure, capital formation cycles tightening, and regulatory expectations rising, teams are pushed to deliver more progress with fewer margins for error. In this environment, a smooth, predictable technology transfer has become essential to keeping programs on track and protecting asset value.
Why timelines slip at transfer
As drug programs move toward manufacturing, familiar obstacles often begin to surface. Even small delays can quickly create knock-on effects. Unexpected technical or operational challenges can interrupt progress and add complexity to the path ahead. Gaps in tacit knowledge, differences in analytical method performance between sites, delays in cleaning validation, or facility‑fit constraints that affect scale‑up and throughput planning are all common friction points.
These issues typically arise because a process developed in one environment does not perfectly align with the realities of another. Small variations in equipment capability, environmental control, containment requirements, or documentation maturity can introduce variability that only becomes visible once manufacturing begins. Likewise, analytical methods that behave consistently at the originating site may require additional robustness work under new laboratory conditions. When these factors aren’t anticipated early, they slow progress at the moment when efficiency and predictability matter most.
As Jon Walton, Head of Technical Process Engineering at Douglas, explains,
“A successful transfer hinges on the ability to share both explicit and tacit knowledge. Explicit knowledge is more straightforward to document and transfer, such as your standard operating procedures and your critical analytical methods. Tacit knowledge is more nuanced and can be more challenging to convey. It is often unspoken and involves subtle and experiential insights. Capturing both types of knowledge is key.”
Safeguard timelines, investment, and plan with confidence
A transfer that runs smoothly, protects timelines, safeguards investment, and gives teams the clarity they need to plan with confidence. That’s why sharing proven approaches and practical experience is so important. When expectations, requirements, and technical pathways are aligned from the outset, far less time is spent recovering lost ground, and far more time is spent advancing the program.
To support that outcome, we’ve assembled deeper guidance on the areas that most strongly influence transfer performance:
- Knowledge transfer
- Equipment and utilities
- Control strategy, and
- Manufacturing strategy
For organisations wanting to minimise risk and maintain momentum, the complete set of insights can be accessed in the downloadable resource below.
What’s inside
- How to capture critical tacit and explicit knowledge to prevent gaps during handover.
- A practical approach to facility and equipment fit, helping avoid scale‑up constraints later.
- Risk‑based analytical method transfer guidance to reduce variability between sites.
- Efficient cleaning validation strategies that help protect development timelines.
- A clear structure for building a robust control strategy from QTPP through CPPs.
Other posts you may be interested in...
Articles
Bespoke client solutions: A personalized approach as a privately owned CDMO
Douglas CDMO is making its mark in the pharmaceutical development industry with their flexible and personalized approaches to client needs.
Learn MoreArticles
Efficient pathways: The regulatory edge of New Zealand for pharmaceutical development
By developing and trialing products in New Zealand, companies can benefit from streamlined processes and potentially accelerate time to market.
Learn MoreArticles
Softgel technology: A game-changer for oncology treatment?
Softgel capsules offer unique advantages in oncology treatment, from enhancing drug delivery to improving patient compliance.
Learn More